Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland

Autoimmune Disease

Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study

Lancet.

van Vollenhoven RF, Hahn BH, Tsokos GC, Wagner CL, Lipsky P, Touma Z, Werth VP, Gordon RM, Zhou B, Hsu B, Chevrier M, Triebel M, Jordan JL, Rose S

doi: 10.1016/S0140-

Systemic Lupus Erythematosus

Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus

Arthritis Res Ther.

Sohrabian A, Parodis I, Carlströmer-Berthén N, Frodlund M, Jönsen A, Zickert A, Sjöwall C, Bengtsson AA, Gunnarsson I, Rönnelid J

doi: 10.1186/s13075-019-2056-y.

Autoimmune DiseaseSystemic Lupus ErythematosusFurther Publications Rheumatology

EMBRACE: Phase 3/4, Randomized, 52-Week Study of Belimumab Efficacy and Safety in Patients of Black African Ancestry With Systemic Lupus Erythematosus

Arthritis Rheumatol

Ginzler E, Guedes Barbosa LS, D'Cruz D, Furie R, Maksimowicz-McKinnon K, Oates J, Santiago MB, Saxena A, Sheikh S, Bass DL, Burriss SW, Gilbride JA, Groark JG, Miller M, Pierce A, Roth DA, Ji B, At the time of the study.

doi: 10.1002/art.41900

Systemic Lupus Erythematosus

Lymphopenia as a risk factor for neurologic involvement and organ damage accrual in patients with systemic lupus erythematosus: A multi-center observational study

Semin Arthritis Rheum.

Yavuz S, Cansu DU, Nikolopoulos D, Crisafulli F, Antunes AM, Adamichou C, Reid S, Stagnaro C, Andreoli L, Tincani A, Moraes-Fontes MF, Mosca M, Leonard D, Jönsen A, Bengtsson A, Svenungsson E, Gunnarsson I, Dahlqvist SR, Sjöwall C, Bertsias G, Fanouriakis A, Rönnblom L

doi: 10.1016/j.semarthrit.2020.02.020.

ImmunomodulationSystemic Lupus Erythematosus

Belimumab restores Treg/Th17 balance in patients with refractory systemic lupus erythematosus

Lupus.

Prete M, Leone P, Frassanito MA, Desantis V, Marasco C, Cicco S, Dammacco F, Vacca A, Racanelli V

doi: 10.1177/0961203318797425.

Systemic Lupus Erythematosus

Additional Improvements in Clinical Response From Adjuvant Biologic Response Modifiers in Adults With Moderate to Severe Systemic Lupus Erythematosus Despite Immunosuppressive Agents: A Systematic Review and Meta-Analysis

Clin Ther.

Shamliyan TA, Dospinescu P

doi: 10.1016/

Systemic Lupus Erythematosus

Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension

Rheumatology (Oxford).

van Vollenhoven RF, Navarra SV, Levy RA, Thomas M, Heath A, Lustine T, Adamkovic A, Fettiplace J, Wang ML, Ji B, Roth D

doi: 10.1093/rheumatology/

Systemic Lupus Erythematosus

Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus

Lupus.

Schwarting A, Dooley MA, Roth DA, Edwards L, Thompson A, Wilson B

doi: 10.1177/0961203316655215

Juvenile Idiopathic ArthritisRheumatoid Arthritis

Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations

Arthritis Res Ther

Unizony S, McCulley TJ, Spiera R, Pei J, Sidiropoulos PN, Best JH, Birchwood C, Pavlov A, Stone JH

doi: 10.1186/s13075-020-02377-8

Related content

Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study

Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus

EMBRACE: Phase 3/4, Randomized, 52-Week Study of Belimumab Efficacy and Safety in Patients of Black African Ancestry With Systemic Lupus Erythematosus

Lymphopenia as a risk factor for neurologic involvement and organ damage accrual in patients with systemic lupus erythematosus: A multi-center observational study

Belimumab restores Treg/Th17 balance in patients with refractory systemic lupus erythematosus

Additional Improvements in Clinical Response From Adjuvant Biologic Response Modifiers in Adults With Moderate to Severe Systemic Lupus Erythematosus Despite Immunosuppressive Agents: A Systematic Review and Meta-Analysis

Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension

Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus

Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations